The Endocrine Outlook: Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

Podcast

This episode of the Endocrine Outlook podcast features a discussion around the cardiorenal benefits of SGLT2 inhibitors and GLP-1 receptor agonists.

In this episode of the Endocrine Outlook, listeners will hear a conversation with Muthiah Vaduganathan, MD, MPH, a cardiologist at Brigham and Women’s hospital. Vaduganathan was also a member of the writing committee for a recent AHA scientific statement regarding the cardiorenal protective benefits of SGLT2 inhibitors and GLP-1 receptor agonists.

In the interview, Vaduganathan offers insight into the writing process and his perspective on how the most recent trials for these agents have added to our understanding of the classes.

Related Videos
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Albert Foa, MD, PhD | Credit: HCPLive
Veraprapas Kittipibul, MD | Credit: X.com
Heart Failure stock imagery. | Credit: Fotolia
© 2024 MJH Life Sciences

All rights reserved.